Moreover, compared to NSCLC that is often characterized by mutations of targetable oncogenes, SCLC frequently exhibits gene alterations in the tumor suppressors P53 and RB (89% and 64% respectively), which are near-universally inactivated (14, 19), hindering the development of targeted therapies. The gene discussed is TP53; the disease is non-small cell lung carcinoma.